ATID-495 was the stock code for a small biotech startup that had a single promising drug candidate: a peptide therapy that could repair damaged nerve sheaths after injury. Investors called it a gamble; clinicians called it "possible game-changer." For Mara, a clinical trial coordinator, it was personal — her younger brother had been in a motorcycle crash two years earlier and still struggled with numbness and weakness.